Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 8,500 | |||
10 mg | 在庫あり | ¥ 12,000 | |||
25 mg | 在庫あり | ¥ 22,500 | |||
50 mg | 在庫あり | ¥ 39,500 | |||
100 mg | 在庫あり | ¥ 68,500 | |||
500 mg | 在庫あり | ¥ 167,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,500 |
ターゲット&IC50 | c-Kit:8 nM, VEGFR2/Flk1:6 nM, VEGFR1:2 nM, VEGFR3:6 nM, VEGFR2:3 nM |
In vitro | In a rat corneal model, administering Motesanib Diphosphate orally twice daily (ED50=2.1 mg/kg) or once daily (ED50=4.9 mg/kg) effectively inhibited vascular endothelial growth factor-induced angiogenesis. Additionally, in a model of transplanted squamous cell carcinoma of the head and neck, the combined use of Motesanib Diphosphate and radiation therapy demonstrated significant anticancer activity. |
In vivo | In human umbilical vein endothelial cells (HUVECs) induced by VEGF (IC50=10 nM), Motesanib Diphosphate significantly inhibits cell proliferation. It also markedly suppresses proliferation prompted by platelet-derived growth factor (IC50=207 nM) and c-kit phosphorylation induced by SCF (IC50=37 nM). Additionally, Motesanib Diphosphate enhances the sensitivity of these cells to radiation and exhibits broad-spectrum activity against the human VEGFR family. |
別名 | Motesanib, AMG 706 |
分子量 | 569.44 |
分子式 | C22H23N5O·2H3PO4 |
CAS No. | 857876-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 16 mg/mL (28.1 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (163.3 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Motesanib Diphosphate 857876-30-3 Angiogenesis Tyrosine Kinase/Adaptors c-Kit VEGFR Motesanib AMG-706 inhibit AMG 706 Diphosphate Vascular endothelial growth factor receptor AMG706 SCFR Inhibitor AMG 706 CD117 inhibitor